Rheumatoid Arthritis

      Presenteeism and absenteeism in RA aren’t just about joints. In this UK study, comorbid anxiety, depression, and OA dr

      Jiha Lee JihaRheum

      4 months 1 week ago
      Presenteeism and absenteeism in RA aren’t just about joints. In this UK study, comorbid anxiety, depression, and OA drove lost productivity. Treating RA is not enough —holistic management matters. POS0403 @RheumNow #EULAR2025
      #RA #recommendations #update

      Some recommendations were merged

      For sure some regions will consider
      #Combination #csDMA

      Janet Pope Janetbirdope

      4 months 1 week ago
      #RA #recommendations #update Some recommendations were merged For sure some regions will consider #Combination #csDMARDs or Switch to another 👇🤔 #sulfasalazine #leflunomide Depends on access, pt preference, disease activity/severity #EULAR2025 @RheumNow @eular_org https://t.co/QDPcHhvQiV
      Tapering in RA?
      In SORAIRO (n=149), pts in remission on ozoralizumab+MTX:
      🧪 49% became MTX-free
      ⏱ 80% spaced OZR to

      Jiha Lee JihaRheum

      4 months 1 week ago
      Tapering in RA? In SORAIRO (n=149), pts in remission on ozoralizumab+MTX: 🧪 49% became MTX-free ⏱ 80% spaced OZR to q8w CDAI ≤10 maintained in >90% if baseline remission + albumin >3.8 LB0006 @RheumNow #EULAR2025
      #EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or b

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or btw RTX-Bs in connective tissue disease. No difference in response/B-cell depletion pre- & post-switch.Only 10% stopped RTX at 5-year.Better than in RA @RheumNow https://t.co/ERPgwQ3gZB
      Recommendations for RA management at #EULAR2025
      - MTX [or other csDMARDs] and steroids still remain the first line- not

      Bella Mehta bella_mehta

      4 months 1 week ago
      Recommendations for RA management at #EULAR2025 - MTX [or other csDMARDs] and steroids still remain the first line- nothing beats that! - ofcourse minimize steroids! - rather than stopping meds at remission, reducing doses may be a better solution. Not much changed. @RheumNow https://t.co/NK5ejsgjWV
      In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more fla

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS. Remission matters for subsequent Tx reduction. @RheumNow #EULAR2025 #LB0006
      The relation between RA, comorbidities and presenteism

      NRAS survey 891 RA pts
      75% had at least one comorbidity

      Absente

      Aurelie Najm AurelieRheumo

      4 months 1 week ago
      The relation between RA, comorbidities and presenteism NRAS survey 891 RA pts 75% had at least one comorbidity Absenteeism more likely if One OR = 1.68 or Two OR = 2.26 comorbid conditions In particular Anxiety OR = 2.39 Depression OR = 1.75 Osteoarthritis OR = 1.85 Back
      RA is worst with temperature rising/ climate change.
      However SpA has the opposite effect!
      Climate change session at #EU

      Bella Mehta bella_mehta

      4 months 1 week ago
      RA is worst with temperature rising/ climate change. However SpA has the opposite effect! Climate change session at #EULAR2025 @RheumNow https://t.co/eKVXnfdEzD
      What do we do when we see Rx signed of CPPD in RA pts? Do these pts have different trajectory?

      Rx Retro study 388 patie

      Aurelie Najm AurelieRheumo

      4 months 1 week ago
      What do we do when we see Rx signed of CPPD in RA pts? Do these pts have different trajectory? Rx Retro study 388 patients RA 18% at least one sign CPPD ns diff between seeonegative and seropositive pts RA+CPPD group was -older -higher comorbidity score -more likely to be https://t.co/DaW5DZoDzF
      Low disease activity more difficult to achieve in vulnerable populations.
      All rheumatic diseases - #RA #PsA #AS
      initia

      Bella Mehta bella_mehta

      4 months 1 week ago
      Low disease activity more difficult to achieve in vulnerable populations. All rheumatic diseases - #RA #PsA #AS initiating DMARDs takes longer in these population #EULAR2025 @RheumNow https://t.co/voIivshKRt
      Does Abatacept Buy You Time Off RA?
      4 months 1 week ago
      acr_session2.jpeg
      EULAR 2025 – Day 3 Report
      4 months 2 weeks ago
      Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.
      👁️Uveitis in axSpA:
      -Up to 40% can present before SpA dx
      -NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i prote

      Adela Castro AdelaCastro222

      4 months 2 weeks ago
      👁️Uveitis in axSpA: -Up to 40% can present before SpA dx -NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i protective effects against uveitis -Low rates of uveitis in axSpA pts on BIME trials suggests its possible beneficial effects. #EULAR2025 @RheumNow https://t.co/mPuSMnD1Zs
      1/3 of #ERA pts poor
      Outcomes despite controlled disease!
      2 #RCT with T2T in early #RA
      #CARERA
      👇
      persistent impact

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      1/3 of #ERA pts poor Outcomes despite controlled disease! 2 #RCT with T2T in early #RA #CARERA 👇 persistent impact ⬆️TJC, comorbidities ⬇️SJC, CRP, global, HAQ,  F>M ⬆️disease durat’n ▶️ ⬆️ b/tsDMARDs despite =diseaese vs others ?overRx OP0330 #EULAR2025 @RheumNow @eular_org
      KORAIL cohort: new RA-ILD progression model (inc. DLCO, ILD pattern/extent, anti-CCP, ± KL-6) stratified risk with high

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      KORAIL cohort: new RA-ILD progression model (inc. DLCO, ILD pattern/extent, anti-CCP, ± KL-6) stratified risk with high sensitivity & specificity. Adding KL-6 boosted AUC to 0.75. A step toward personalised care in RA-ILD. @RheumNow #EULAR2025 #OP0328 https://t.co/AHqNFw40gk

      Catch up on Conference Podcasts

      ×